NASDAQ:NXTC NextCure (NXTC) Stock Price, News & Analysis $1.78 -0.29 (-14.01%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$1.79 +0.01 (+0.56%) As of 07/7/2026 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About NextCure Stock (NASDAQ:NXTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NextCure alerts:Sign Up Key Stats Today's Range$1.76▼$2.1250-Day Range$1.60▼$10.7252-Week Range$1.55▼$15.74Volume82,135 shsAverage Volume114,874 shsMarket Capitalization$6.43 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingHold Company Overview NextCure, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development. The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation. Lead programs such as NX-1607, an oral small molecule inhibitor targeting the CD200 checkpoint, and NX-0255, a monoclonal antibody directed against KIR3DL2, are being developed for solid tumors and hematologic malignancies. NextCure is also advancing NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, into studies for B-cell malignancies. Strategic partnerships with global pharmaceutical companies support NextCure’s efforts to expand its research capabilities and accelerate clinical programs across oncology and immunology indications. Founded in 2013 and headquartered in Beltsville, Maryland, NextCure operates state‐of‐the‐art research and development facilities in the greater Washington, D.C. area. The company conducts clinical trials across North America and Europe, collaborating with leading academic institutions and healthcare centers. By combining novel target discovery with rigorous translational and clinical research, NextCure seeks to bring new immunotherapeutic options to patients worldwide.AI Generated. May Contain Errors. Read More NextCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreNXTC MarketRank™: NextCure scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingNextCure has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNextCure has a consensus price target of $16.50, representing about 827.0% upside from its current price of $1.78.Amount of Analyst CoverageNextCure has only been the subject of 2 research reports in the past 90 days.Read more about NextCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NextCure are expected to decrease in the coming year, from ($7.90) to ($9.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NextCure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.09% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 1.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently increased by 228.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentNextCure has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.MarketBeat Follows2 people have added NextCure to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have not sold or bought any company stock.Percentage Held by Insiders11.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NextCure's insider trading history. Receive NXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NXTC Stock News HeadlinesNextCure, Inc. (NASDAQ:NXTC) Short Interest Up 228.4% in JuneJune 30, 2026 | americanbankingnews.comNextCure, Inc. (NASDAQ:NXTC) Receives Average Recommendation of "Hold" from BrokeragesJune 27, 2026 | americanbankingnews.com$2 an acre. They paid $412.Government land listed at $2 an acre sold for $412 - 206 times asking price. Demand got so intense the feds doubled auction frequency on geothermal rights in the same Utah desert where a drilling crew hit 2035 targets twelve years early. Google signed a 15-year deal. Gates wrote the check. One company controls the entire chain. August 18th, the next auction hits that exact territory - and the whole industry is watching.July 8 at 1:00 AM | Behind the Markets (Ad)NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic CancersJune 4, 2026 | globenewswire.comNextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma TranscriptJune 2, 2026 | seekingalpha.comNextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026June 1, 2026 | globenewswire.comNextCure (NXTC) Stock Forecast & Price TargetMay 25, 2026 | investing.comLucid Capital Markets initiates coverage of NextCure (NXTC) with buy recommendationMay 11, 2026 | msn.comSee More Headlines NXTC Stock Analysis - Frequently Asked Questions How have NXTC shares performed this year? NextCure's stock was trading at $14.19 at the start of the year. Since then, NXTC shares have decreased by 87.5% and is now trading at $1.78. How were NextCure's earnings last quarter? NextCure, Inc. (NASDAQ:NXTC) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($1.87) EPS for the quarter, beating the consensus estimate of ($2.11) by $0.24. When did NextCure's stock split? Shares of NextCure reverse split on the morning of Monday, July 14th 2025.The 1-12 reverse split was announced on Friday, June 20th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did NextCure IPO? NextCure (NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO. How do I buy shares of NextCure? Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings5/07/2026Today7/08/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NXTC's financial health is in the Red zone, according to TradeSmith. NXTC has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NXTC CIK1661059 Webwww.nextcure.com Phone(240) 399-4900FaxN/AEmployees90Year Founded2015Price Target and Rating Average Price Target for NextCure$16.50 High Price Target$18.00 Low Price Target$15.00 Potential Upside/Downside+827.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($17.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-186.96% Return on Assets-124.62% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio4.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.97 per share Price / Book0.18Miscellaneous Outstanding Shares3,610,000Free Float3,182,000Market Cap$6.43 million OptionableNo Data Beta1.42 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NXTC) was last updated on 7/8/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: “This Could Be Bigger Than Nvidia”Fox News contributor Louis Navellier recently sat down to reveal details on Elon Musk's little-known AI projec...InvestorPlace | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
